Besides, Huang et al. reported that in gastric cancer cells, famotidine, a gastric antisecretory drug, could promote the activation of NLRP3 inflammasomes by upregulating expression of NLRP3, ASC, and Caspase-1, then enhance IL-18, not IL-1β, mature and secretion, thus trigger cell pyroptosis and aggravate inflammation, which was considered to be critical in development of gastric cancer (Huang et al., 2021). Here, CASP1 is linked to gastric cancer.